MOLN · Molecular Partners AG ADR
United States · RS rating 21 · As of 2026-11-03
| Price | 3.09 USD |
|---|---|
| 1-day change | -11.2% |
| RS rating (overall / 1M / 3M / 12M) | 21 / 20 / 25 / 40 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 18 / 8 / 23 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +0.0% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +39.7% |
| Market cap (USD) | $164.6M |